{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:50:45Z","timestamp":1783731045355,"version":"3.55.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100015371","name":"ReCor Medical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015371","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ultrasound renal sympathetic denervation (uRDN) reduces blood pressure (BP) in the absence and presence of antihypertensive treatment at 2\u00a0months. Beyond 3\u00a0years, there is a lack of follow-up data. This study investigated the long-term safety and efficacy of uRDN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This prospective observational study recruited patients previously included in the international multicenter ACHIEVE study, with office systolic blood pressure (SBP) \u2265160 mmHg, 24\u00a0h ambulatory SBP \u2265130\u00a0mmHg, \u22653 antihypertensive drugs and\n                      <jats:italic>estimated Glomerular Filtration Rate<\/jats:italic>\n                      (eGFR) \u226545 ml\/min\/1.73m\n                      <jats:sup>2<\/jats:sup>\n                      undergoing uRDN. The primary efficacy outcome was 24\u00a0h ambulatory SBP, adjusted for the number of defined daily dosages (DDD) of antihypertensive drugs. Statistical analyses were performed using linear mixed-effects models and inverse probability weighting.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 27 out of the initially enrolled 96 patients underwent prospective follow-up at a median of 8.2 [7.6\u22128.9]\u00a0years. Mean age was 62.6\u00b19.3\u00a0years (37.0% female). Preprocedural 24\u00a0h ambulatory BP was 151.9\/84.1\u00b111.5\/11.1 mmHg and the median number of DDDs was 5.0 [4.3\u22127.0]. At 8\u00a0years after uRDN, the change in 24\u00a0h ambulatory SBP was \u221219.5 [95%CI \u221226.7,\u221212.4] mmHg (\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.001). The 8-year change in the number of DDDs was \u22121.7 [\u22122.8,\u22120.6] (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.003). The 8-year decline in eGFR was \u22128.9 [\u221213.2,\u22124.7] ml\/min\/1.73m\n                      <jats:sup>2<\/jats:sup>\n                      (\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.001). Clinical event data were available for all 96 patients (median follow-up 3.5 [1.0\u20138.0]\u00a0years). Renal failure occurred in one patient and no cases of renal artery stenosis were detected.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A significant BP reduction was observed up until 8\u00a0years following uRDN in parallel to a decrease in drug burden over time, in the absence of procedure-related adverse events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00392-024-02555-7","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T08:02:57Z","timestamp":1729670577000},"page":"1327-1336","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Long-term safety and efficacy of endovascular ultrasound renal denervation in resistant hypertension: 8-year results from the ACHIEVE study"],"prefix":"10.1007","volume":"115","author":[{"given":"Victor J. M.","family":"Zeijen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"V\u00f6lz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Zeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Mahfoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kunz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Heinz","family":"Kuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bert","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Graf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horst","family":"Sievert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Kahlert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meital","family":"Horesh-Bar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattie J.","family":"Lenzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Kardys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8628-1410","authenticated-orcid":false,"given":"Joost","family":"Daemen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"issue":"10285","key":"2555_CR1","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","volume":"397","author":"Blood Pressure Lowering Treatment Trialists C","year":"2021","unstructured":"Blood Pressure Lowering Treatment Trialists C (2021) Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 397(10285):1625\u201336","journal-title":"Lancet."},{"issue":"10022","key":"2555_CR2","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","volume":"387","author":"D Ettehad","year":"2016","unstructured":"Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J et al (2016) Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 387(10022):957\u201367","journal-title":"Lancet."},{"key":"2555_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ijcard.2022.02.014","volume":"352","author":"VJM Zeijen","year":"2022","unstructured":"Zeijen VJM, Lafeber M, Versmissen J, Kroon AA, Boersma E, Daemen J (2022) Adequacy of blood pressure control in high-risk hypertensive patients: The DEGREE study. Int J Cardiol. 352:137\u201343","journal-title":"Int J Cardiol."},{"issue":"10304","key":"2555_CR4","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","volume":"398","author":"Risk Factor Collaboration NCD","year":"2021","unstructured":"Risk Factor Collaboration NCD (2021) Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 398(10304):957\u201380","journal-title":"Lancet."},{"issue":"20","key":"2555_CR5","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1901281","volume":"384","author":"CE Lewis","year":"2021","unstructured":"Sprint Research Group, Lewis CE, Fine LJ, Beddhu S, Cheung AK, Cushman WC et al (2021) Final Report of a Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 384(20):1921\u201330","journal-title":"N Engl J Med."},{"issue":"10137","key":"2555_CR6","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1016\/S0140-6736(18)31082-1","volume":"391","author":"M Azizi","year":"2018","unstructured":"Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Davies J et al (2018) Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 391(10137):2335\u201345","journal-title":"Lancet."},{"issue":"10293","key":"2555_CR7","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/S0140-6736(21)00788-1","volume":"397","author":"M Azizi","year":"2021","unstructured":"Azizi M, Sanghvi K, Saxena M, Gosse P, Reilly JP, Levy T et al (2021) Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet. 397(10293):2476\u201386","journal-title":"Lancet."},{"issue":"8","key":"2555_CR8","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1001\/jama.2023.0713","volume":"329","author":"M Azizi","year":"2023","unstructured":"Azizi M, Saxena M, Wang Y, Jenkins JS, Devireddy C, Rader F et al (2023) Endovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical Trial. JAMA. 329(8):651\u201361","journal-title":"JAMA."},{"key":"2555_CR9","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jamacardio.2023.0338","volume":"8","author":"AJ Kirtane","year":"2023","unstructured":"Kirtane AJ, Sharp ASP, Mahfoud F, Fisher NDL, Schmieder RE, Daemen J et al (2023) Patient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO Trials. JAMA Cardiol. 8:464","journal-title":"JAMA Cardiol."},{"issue":"9","key":"2555_CR10","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1097\/HJH.0000000000002120","volume":"37","author":"J Daemen","year":"2019","unstructured":"Daemen J, Mahfoud F, Kuck KH, Andersson B, Bohm M, Graf T et al (2019) Safety and efficacy of endovascular ultrasound renal denervation in resistant hypertension: 12-month results from the ACHIEVE study. J Hypertens. 37(9):1906\u201312","journal-title":"J Hypertens."},{"issue":"22","key":"2555_CR11","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1161\/CIRCULATIONAHA.119.040451","volume":"139","author":"M Azizi","year":"2019","unstructured":"Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Lobo MD et al (2019) Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control Following Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial. Circulation. 139(22):2542\u201353","journal-title":"Circulation."},{"issue":"24","key":"2555_CR12","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1016\/j.jcin.2020.09.054","volume":"13","author":"M Azizi","year":"2020","unstructured":"Azizi M, Daemen J, Lobo MD, Mahfoud F, Sharp ASP, Schmieder RE et al (2020) 12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation. JACC Cardiovasc Interv. 13(24):2922\u201333","journal-title":"JACC Cardiovasc Interv."},{"issue":"12","key":"2555_CR13","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1001\/jamacardio.2022.3904","volume":"7","author":"M Azizi","year":"2022","unstructured":"Azizi M, Mahfoud F, Weber MA, Sharp ASP, Schmieder RE, Lurz P et al (2022) Effects of Renal Denervation vs Sham in Resistant Hypertension After Medication Escalation: Prespecified Analysis at 6 Months of the RADIANCE-HTN TRIO Randomized Clinical Trial. JAMA Cardiol. 7(12):1244\u201352","journal-title":"JAMA Cardiol."},{"issue":"8","key":"2555_CR14","doi-asserted-by":"publisher","first-page":"e677","DOI":"10.4244\/EIJ-D-22-00305","volume":"18","author":"F Rader","year":"2022","unstructured":"Rader F, Kirtane AJ, Wang Y, Daemen J, Lurz P, Sayer J et al (2022) Durability of blood pressure reduction after ultrasound renal denervation: three-year follow-up of the treatment arm of the randomised RADIANCE-HTN SOLO trial. EuroIntervention. 18(8):e677\u2013e85","journal-title":"EuroIntervention."},{"issue":"3","key":"2555_CR15","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1161\/HYPERTENSIONAHA.118.12250","volume":"73","author":"RR Singh","year":"2019","unstructured":"Singh RR, McArdle ZM, Iudica M, Easton LK, Booth LC, May CN et al (2019) Sustained Decrease in Blood Pressure and Reduced Anatomical and Functional Reinnervation of Renal Nerves in Hypertensive Sheep 30 Months After Catheter-Based Renal Denervation. Hypertension. 73(3):718\u201327","journal-title":"Hypertension."},{"key":"2555_CR16","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. DDD - Definition and general considerations: WHO Collaborating Centre for Drug Statistics Methodology; 2018 [updated 2018\/07\/02. Available from: https:\/\/www.whocc.no\/ddd\/definition_and_general_considera\/."},{"key":"2555_CR17","unstructured":"R Core Team. R version 4.3.0 'Already Tomorrow'. 2023, April 21."},{"issue":"10234","key":"2555_CR18","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/S0140-6736(20)30554-7","volume":"395","author":"M Bohm","year":"2020","unstructured":"Bohm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE et al (2020) Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 395(10234):1444\u201351","journal-title":"Lancet."},{"issue":"10137","key":"2555_CR19","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1016\/S0140-6736(18)30951-6","volume":"391","author":"DE Kandzari","year":"2018","unstructured":"Kandzari DE, Bohm M, Mahfoud F, Townsend RR, Weber MA, Pocock S et al (2018) Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 391(10137):2346\u201355","journal-title":"Lancet."},{"issue":"42","key":"2555_CR20","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1093\/eurheartj\/ehz118","volume":"40","author":"F Mahfoud","year":"2019","unstructured":"Mahfoud F, Bohm M, Schmieder R, Narkiewicz K, Ewen S, Ruilope L et al (2019) Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry. Eur Heart J. 40(42):3474\u201382","journal-title":"Eur Heart J."},{"key":"2555_CR21","first-page":"87","volume":"40","author":"VJM Zeijen","year":"2022","unstructured":"Zeijen VJM, Feyz L, Nannan Panday R, Veen K, Versmissen J, Kardys I et al (2022) Long-term follow-up of patients undergoing renal sympathetic denervation. Clin Res Cardiol. 40:87","journal-title":"Clin Res Cardiol."},{"issue":"4","key":"2555_CR22","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1161\/HYPERTENSIONAHA.122.20853","volume":"80","author":"G Sesa-Ashton","year":"2023","unstructured":"Sesa-Ashton G, Nolde JM, Muente I, Carnagarin R, Lee R, Macefield VG et al (2023) Catheter-Based Renal Denervation: 9-Year Follow-Up Data on Safety and Blood Pressure Reduction in Patients With Resistant Hypertension. Hypertension. 80(4):811\u20139","journal-title":"Hypertension."},{"issue":"5","key":"2555_CR23","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.jacc.2022.11.038","volume":"81","author":"H Al Ghorani","year":"2023","unstructured":"Al Ghorani H, Kulenthiran S, Recktenwald MJM, Lauder L, Kunz M, Gotzinger F et al (2023) 10-Year Outcomes of Catheter-Based Renal Denervation in Patients With Resistant Hypertension. J Am Coll Cardiol. 81(5):517\u20139","journal-title":"J Am Coll Cardiol."},{"issue":"10333","key":"2555_CR24","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/S0140-6736(22)00455-X","volume":"399","author":"F Mahfoud","year":"2022","unstructured":"Mahfoud F, Kandzari DE, Kario K, Townsend RR, Weber MA, Schmieder RE et al (2022) Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. Lancet. 399(10333):1401\u201310","journal-title":"Lancet."},{"issue":"12","key":"2555_CR25","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.1016\/j.ekir.2021.10.006","volume":"6","author":"AC van der Burgh","year":"2021","unstructured":"van der Burgh AC, Rizopoulos D, Ikram MA, Hoorn EJ, Chaker L (2021) Determinants of the Evolution of Kidney Function With Age. Kidney Int Rep. 6(12):3054\u201363","journal-title":"Kidney Int Rep."},{"issue":"4","key":"2555_CR26","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1093\/ije\/dyu080","volume":"43","author":"K Bhaskaran","year":"2014","unstructured":"Bhaskaran K, Smeeth L (2014) What is the difference between missing completely at random and missing at random? Int J Epidemiol. 43(4):1336\u20139","journal-title":"Int J Epidemiol."}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-024-02555-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-024-02555-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-024-02555-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T07:05:24Z","timestamp":1783494324000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-024-02555-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2555"],"URL":"https:\/\/doi.org\/10.1007\/s00392-024-02555-7","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,23]]},"assertion":[{"value":"23 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"F. Mahfoud is supported by Deutsche Gesellschaft f\u00fcr Kardiologie (DGK), Deutsche Forschungsgemeinschaft (SFB TRR219, Project-ID 322900939), and Deutsche Herzstiftung and he has received scientific support from Ablative Solutions, Medtronic and ReCor Medical and speaker honoraria\/consulting fees from Ablative Solutions, Amgen, Astra-Zeneca, Bayer, Boehringer Ingelheim, Inari, Medtronic, Merck, ReCor Medical, Servier, and Terumo. M. Horesh-Bar is an employee of ReCor Medical. J. Daemen received institutional grant\/research support from ACIST Medical, Abbott Vascular, Boston Scientific, Medtronic, Microport, Pie Medical, and ReCor medical, and consultancy and speaker fees from Abbott Vascular, Abiomed, ACIST medical, Boston Scientific, Cardialysis BV, CardiacBooster, Kaminari Medical, Medtronic, PulseCath, Pie Medical, ReCor Medical, Sanofi and Siemens Health Care.\u00a0All other authors\u00a0declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}